Sarcoidosis of the lung is a chronic inflammatory condition in which clusters of immune cells called granulomas form in the lung tissue and nearby lymph nodes, often causing a persistent dry cough, shortness of breath, and fatigue. The lungs are involved in roughly nine out of ten cases of sarcoidosis, making pulmonary disease the most common and most studied form. While many people with pulmonary sarcoidosis recover without treatment, a significant minority develop progressive scarring, declining lung function, or complications that require years of therapy. The disease is more common and more severe in certain populations, and recent research has shed light on why.
How Pulmonary Sarcoidosis Develops
Sarcoidosis begins when the immune system overreacts to a trigger that, in most cases, is never identified. The hallmark is the granuloma: a tiny ball of inflammatory cells, primarily immune cells called macrophages, surrounded by a ring of activated T cells. In the lungs, these granulomas can cluster along the airways, around blood vessels, and within lymph nodes in the chest. In acute sarcoidosis, a specific type of T cell that recognizes the body’s own protein vimentin accumulates in granulomas and releases a potent mix of inflammatory signals, including interferon-gamma and interleukin-17.1PubMed. Mechanism of granuloma formation in sarcoidosis This immune response can simmer and resolve, or it can persist and eventually lead to fibrosis, the irreversible scarring that drives permanent lung damage.
What sets the whole process in motion is still debated. There is no single known cause, and many researchers suspect that sarcoidosis reflects an exaggerated immune response to one of several possible environmental or microbial triggers in someone who is genetically susceptible. That combination of environment and genes explains why the disease clusters in families and varies dramatically by race and geography.
Who Gets Pulmonary Sarcoidosis
Sarcoidosis affects people of all backgrounds, but the risk and the severity differ sharply by race. In the United States, Black patients experience more severe lung disease, more involvement of other organs, and higher rates of hospitalization and death compared to White patients.2PubMed Central. Sarcoidosis Epidemiology: Race Matters A large multicenter study found that Black patients were roughly three times as likely to have multiple organs affected and had higher rates of neurological, skin, eye, liver, and spleen involvement.3PubMed Central. The impact of demographic disparities in the presentation of sarcoidosis: A multicenter prospective study Women in that same study were more likely to have eye or skin involvement, while men were more likely to develop cardiac sarcoidosis.
Part of this disparity traces to genetics. Certain variants in the HLA-DRB1 gene, which helps the immune system distinguish self from non-self, are strongly linked to sarcoidosis risk. One allele, HLA-DRB1*1101, has been identified as a significant risk factor in both Black and White patients, with a population-attributable risk of about 16 percent in Black individuals and 9 percent in White individuals.4PubMed Central. HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites Additional research in African Americans found that the HLA-DRB1*12:01 and *11:01 alleles were associated with increased disease susceptibility, while the *03:01 allele appeared protective.5PubMed Central. Association of HLA-DRB1 with Sarcoidosis Susceptibility and Progression in African Americans Having a protective allele does not guarantee you will never get sarcoidosis, and having a risk allele does not mean you will. But these genetic profiles help explain why the disease hits some populations harder.
Symptoms and Patterns of Lung Involvement
The classic symptoms of pulmonary sarcoidosis are a dry cough, breathlessness on exertion, and chest discomfort. Many people also report fatigue that feels out of proportion to the lung disease itself. Symptoms can be subtle or entirely absent, and it is not unusual for the diagnosis to come after an incidental finding on a chest X-ray done for another reason. Lung function tests and imaging often correlate poorly with how a patient actually feels day to day.6PubMed Central. The Symptoms of Pulmonary Sarcoidosis
A dramatic and recognizable pattern is Löfgren syndrome, an acute form of sarcoidosis characterized by fever, swollen lymph nodes in both sides of the chest, joint inflammation, and a painful red rash on the shins. In one large study of 691 patients, about 45 percent presented with Löfgren syndrome, and this group was younger, more often female, and overwhelmingly Caucasian compared to the non-Löfgren group.7PubMed. Sarcoidosis presenting with and without Löfgren’s syndrome Löfgren syndrome carries a good prognosis. In the same study, none of the Löfgren patients had advanced radiological stages at diagnosis, and only about 19 percent needed systemic treatment. By contrast, roughly two-thirds of non-Löfgren patients had disease lasting longer than two years, and nearly 60 percent required treatment.
Imaging and Staging
Pulmonary sarcoidosis has traditionally been staged using the chest X-ray in a system known as Scadding staging: stage 0 means a normal X-ray, stage I shows enlarged lymph nodes in the chest without lung involvement, stage II adds lung infiltrates, stage III has lung infiltrates without lymph node enlargement, and stage IV indicates pulmonary fibrosis. These stages were designed decades ago and remain widely used, but they are imperfect predictors of lung function.
High-resolution CT scans pick up significantly more detail. One study comparing chest X-ray with CT found that more than half of patients had discordant staging between the two methods.8PubMed Central. Chest high-resolution computed tomography can make higher accurate stages for thoracic sarcoidosis than X-ray The most common reasons for the mismatch were that X-rays missed enlarged lymph nodes hidden behind the heart and small lung nodules below the X-ray’s resolution. CT-based staging correlated with the lung’s gas-exchange capacity while chest X-ray staging did not. A separate study using a CT-based severity score found moderate correlations between the score and several functional measures, including lung volume, gas exchange, and exercise capacity, and these correlations were stronger than those seen with the traditional Scadding system.9PubMed Central. Relationship Between Thoracic CT Severity Score and Scadding Staging With PFT, DLCO, and 6MWT in Patients With Sarcoidosis
How the Diagnosis Is Confirmed
Diagnosing sarcoidosis is often a process of exclusion. There is no single blood test that confirms it. A tissue biopsy showing non-caseating granulomas, after ruling out infections like tuberculosis and fungal disease, remains the gold standard. Bronchoscopy with endobronchial ultrasound-guided needle aspiration (EBUS-TBNA) has become the preferred way to sample chest lymph nodes. In one study, the diagnostic accuracy of EBUS-TBNA alone was about 84 percent, rising to 89 percent when combined with other bronchoscopic techniques.10PubMed. The role of EBUS-TBNA and standard bronchoscopic modalities in the diagnosis of sarcoidosis A more recent analysis reported sensitivity of around 85 percent for EBUS-TBNA across the full cohort, with higher sensitivity (94 percent) in patients who had stage I disease on chest X-ray.11PubMed Central. Impact of Rapid Cytologic Evaluation of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration on the Value of Adjunctive Transbronchial Biopsy in Sarcoidosis
Bronchoalveolar lavage, where fluid is washed into and recovered from the airways, is sometimes performed alongside biopsy. A high ratio of CD4 to CD8 T cells in the lavage fluid has historically been considered supportive of a sarcoidosis diagnosis. In practice, the test is unreliable. One study of biopsy-proven sarcoidosis patients found the CD4/CD8 ratio ranged enormously, from 0.5 to over 37, and fewer than half had a ratio above the classic cutoff of 4. About 12 percent actually had a ratio below 1, which would normally point away from sarcoidosis.12European Respiratory Journal. The CD4/CD8 ratio in BAL fluid is highly variable in sarcoidosis The lavage can still provide useful supporting information, but it cannot rule sarcoidosis in or out on its own.
Lung Function Patterns
Sarcoidosis can produce almost any pattern on a pulmonary function test. The most common abnormality is a restrictive pattern, where the lungs cannot expand fully, seen in about 45 percent of patients with lung involvement.13PubMed Central. Pulmonary Function in Pulmonary Sarcoidosis Some patients instead show an obstructive pattern, where airflow is limited on the way out, similar to asthma or chronic obstructive lung disease. Others show reduced gas exchange capacity without obvious restriction or obstruction, or a combination of all of these. This variability means clinicians cannot rely on a single lung function pattern to make or confirm the diagnosis. Serial measurements over time matter more than any single snapshot, because trends in lung function are what guide treatment decisions.
Treatment
Not everyone with pulmonary sarcoidosis needs treatment. In many cases, especially Löfgren syndrome and early-stage disease without significant symptoms, the condition resolves on its own within a couple of years. Treatment is generally reserved for patients with worsening lung function, significant symptoms, or involvement of critical organs like the heart, brain, or eyes.
When systemic therapy is needed, corticosteroids are still the first choice. Most experts recommend starting with oral prednisone at 20 to 40 milligrams per day for treatment-naïve patients, with lower doses for slowly progressive disease.14PubMed Central. A Comprehensive Review of Sarcoidosis Treatment for Pulmonologists The problem is that once steroids are started, there is a greater than 50 percent chance the patient will end up on long-term treatment, and prolonged use at moderate-to-high doses brings predictable side effects: weight gain, bone loss, high blood sugar, and vulnerability to infections.
For patients who cannot taper off steroids or who develop significant side effects, steroid-sparing agents are added. Methotrexate and azathioprine are the most commonly used. In a head-to-head comparison, both drugs showed similar ability to reduce the daily prednisone dose, with 70 percent of patients able to cut their steroid dose by at least 10 milligrams per day after a year. Lung function modestly improved in both groups. Infections were more common with azathioprine, occurring in about 35 percent of that group compared to 18 percent on methotrexate.15PubMed. Methotrexate vs azathioprine in second-line therapy of sarcoidosis
For truly refractory disease, biologic agents enter the picture. Infliximab, a drug that blocks the inflammatory signal TNF-alpha, has shown benefit in patients whose sarcoidosis does not respond to conventional therapy. In one study of patients with active, refractory disease confirmed by PET imaging, lung capacity improved by an average of about 7 percent predicted after six months of infliximab, reversing a prior decline.16European Respiratory Journal. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis A multicenter analysis of 33 refractory patients reported treatment success in roughly 79 percent of pulmonary cases and allowed a 50 percent reduction in steroid dose overall.17PubMed Central. Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis
Pulmonary Hypertension as a Complication
One of the more serious complications of pulmonary sarcoidosis is elevated blood pressure in the lung’s arteries. This complication is most common in patients who already have pulmonary fibrosis, but it can also develop in patients without significant scarring, suggesting that sarcoidosis can directly damage the lung’s blood vessels.18PubMed Central. Sarcoidosis-associated Pulmonary Hypertension: Pathophysiology, Diagnosis, and Treatment Possible mechanisms include compression of blood vessels by enlarged lymph nodes, direct granulomatous inflammation of vessel walls, and in rare cases, a form of veno-occlusive disease. Survival in patients with sarcoidosis-associated pulmonary hypertension is worse than in those without it. One study reported five-year survival of only 59 percent, with outcomes tied to how limited the patient’s exercise capacity had become rather than to the pressure measurements themselves.19Thorax. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis In that study, corticosteroids helped some patients without fibrosis but were ineffective in those who already had extensive scarring.
Prognosis and What Predicts It
Most people diagnosed with pulmonary sarcoidosis do well. Spontaneous remission occurs in a large proportion of cases, particularly among those with early-stage disease, normal lung function at diagnosis, and no symptoms requiring treatment. Factors that predict a good outcome include low radiological stage, preserved lung capacity and gas exchange, being asymptomatic, and having never needed treatment.20PubMed Central. Prognosis of sarcoidosis and factors affecting prognosis Conversely, rising inflammatory markers and declining spirometry values signal progression. Black race, older age at diagnosis, non-Löfgren presentation, and advanced radiological stage at the time of diagnosis are all associated with a more chronic course.
The Löfgren pattern, as described earlier, is especially reassuring. Almost all patients with this presentation recover fully. The non-Löfgren group is more heterogeneous: some remit, some smolder for years, and a minority progress to end-stage fibrosis requiring lung transplantation. The challenge for clinicians is identifying early on which patients in this group will need aggressive treatment.
The Vitamin D and Calcium Quirk
Sarcoidosis has an unusual relationship with vitamin D that catches many patients off guard. The granulomas contain activated macrophages that possess an enzyme capable of converting the storage form of vitamin D into its active form. Because this enzyme operates outside the body’s normal feedback controls, active vitamin D can build up to high levels, which in turn pulls too much calcium into the bloodstream.21PubMed Central. Calcium and vitamin D in sarcoidosis: how to assess and manage This means that taking vitamin D supplements, which might seem like a sensible thing to do if a blood test shows a low storage level, can actually provoke a dangerous spike in blood calcium. Case reports have documented sarcoidosis patients developing full-blown hypercalcemia after receiving a standard vitamin D loading dose.22European Respiratory Journal. Hypercalcaemia in asymptomatic sarcoidosis unmasked by a vitamin D loading dose If you have sarcoidosis and a provider recommends vitamin D supplementation, both 25-hydroxy and 1,25-dihydroxy vitamin D levels, along with serum and urine calcium, should be monitored.
Fatigue, Sleep, and Cognitive Fog
Ask patients what bothers them most about sarcoidosis, and a surprising number will say fatigue rather than cough or shortness of breath. Sarcoidosis fatigue is complex and does not always track with how active the lung disease is. A prospective study of nearly 300 sarcoidosis outpatients found that the strongest predictors of fatigue at six and twelve months were everyday cognitive problems and depressive symptoms, not lung function.23PubMed. Everyday cognitive failure and depressive symptoms predict fatigue in sarcoidosis: A prospective follow-up study Sleep disturbance is another frequent complaint, and it strongly correlates with fatigue, depression, and reduced quality of life.24PubMed. Sleep disturbance and symptom burden in sarcoidosis These findings have shifted how specialists think about managing sarcoidosis. Suppressing granulomatous inflammation is only part of the picture; addressing cognitive symptoms, mood, and sleep can meaningfully improve how patients feel and function even if their chest scans look the same.
Environmental and Occupational Triggers
Although sarcoidosis has no confirmed single cause, occupational and environmental exposures have drawn increasing attention. A systematic review and meta-analysis identified several categories of toxic particles associated with a higher risk of developing pulmonary sarcoidosis, including silica dust, pesticides, and mold or mildew exposure.25BMJ. Occupational exposure to toxic particles and risk of pulmonary sarcoidosis: a systematic review and meta-analysis Exposure to World Trade Center dust after the September 11 attacks was also linked to increased odds of the disease, and this association held up in sensitivity analysis. Interestingly, gold exposure appeared protective, though the mechanism for that finding remains unclear. These associations do not prove causation, but they reinforce the idea that inhaled environmental particles may act as triggers in genetically predisposed people.
Newer Biomarkers for Tracking Disease Activity
One of the frustrations of managing pulmonary sarcoidosis is the lack of a reliable blood test to track disease activity over time. Serum angiotensin-converting enzyme (ACE) was the traditional marker, but it is neither sensitive nor specific enough to guide treatment on its own.26PubMed. Predictive value of gallium scan, angiotensin-converting enzyme level, and bronchoalveolar lavage in two-year follow-up of pulmonary sarcoidosis Soluble interleukin-2 receptor (sIL-2R) has emerged as a more promising alternative. It is released by activated T cells and can help distinguish sarcoidosis patients from healthy controls, differentiate active from inactive disease, and gauge response to treatment.27PubMed Central. Biological role of the soluble interleukin-2 receptor in sarcoidosis Patients with lung involvement who had visible lesions on imaging tended to have higher sIL-2R levels, and those who went on to worsen on follow-up imaging had higher baseline levels as well.28PubMed Central. The clinical value of serum soluble interleukin-2 receptor in pulmonary sarcoidosis While sIL-2R testing is not yet universally adopted, it is increasingly used at specialized centers to guide decisions about when to start, escalate, or taper therapy.
Cardiac Screening in Lung-Predominant Disease
Even when sarcoidosis appears confined to the lungs, cardiac involvement is an underrecognized risk. Granulomas can form in the heart muscle, potentially causing arrhythmias, heart block, or heart failure, sometimes without any cardiac symptoms. Specialized centers now screen pulmonary sarcoidosis patients for cardiac involvement using a combination of clinical criteria, cardiac MRI, and PET imaging.29PubMed Central. Prognostic impact of (18)F-fluorodeoxyglucose positron emission tomography and cardiac magnetic resonance-proven cardiac involvement in pulmonary sarcoidosis The rationale is that cardiac sarcoidosis caught early can be treated with immunosuppression and, where needed, devices like pacemakers or defibrillators, while undetected cardiac involvement carries a risk of sudden death. Men with sarcoidosis appear to be at higher risk for cardiac disease than women, and any patient with unexplained palpitations, fainting, or new heart failure symptoms should be evaluated promptly.